Phase I/II clinical trials have indicated that AZD4547 can target cancers, such as gastric/esophagogastric, bladder, gastric adenocarcinoma, lung and breast, with FGFR1 and -2 amplifications [213,214,215,216,217,218,219,220]. Here, FGFR1 is linked to cancer.